Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2023

Earnings data Q2 2023

Aptevo Therapeutics

Beam Therapeutics

Chimerix

Dynavax Technologies

iTeos Therapeutics, Inc.

Vir Biotechnology

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer Eben Tessari - Chief Operating Officer John Paolini - Chief Medical Officer Conference Call Participants Anupam Rama - JP Morgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Geoff Meacham - Bank of America Liisa Bayko - Evercore ISI Operator Good day, and thank you for standing by.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 2022 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates

– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively –

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023

Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting

HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?

Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 72.7% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 73% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 76.32% and 12.27%, respectively, for the quarter ended September 2022.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q3 Earnings Estimates

– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p

Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at 8:30 a.m. Eastern Time to report its third quarter 2022 financial results and corporate activities.

Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022

Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.

What Makes Kiniksa Pharmaceuticals, Ltd. (KNSA) a Good Fit for "Trend Investing"

Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's Why

HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the closing of the global license agreement with Roche and Genentech, a member of the Roche Group (Genentech), for the rights to develop and commercialize vixarelimab, a fully human monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976.

Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab

The consensus price target hints at a 106% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Kiniksa Pharmaceuticals, Ltd. (KNSA) Climb 106% to Reach the Level Wall Street Analysts Expect?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer Eben Tessari - Chief Operating Officer Mark Ragosa - Chief Financial Officer Ross Moat - Chief Commercial Officer Conference Call Participants Jason Zemansky - Bank of America Anupam Rama - JPMorgan Operator Good morning and welcome to the Kiniksa Pharmaceuticals Second Quarter 2022 Financial Earnings Conference Call.

Kiniksa Pharmaceuticals, Ltd. (KNSA) CEO Sanj Patel on Q2 2022 Results - Earnings Call Transcript

The average of price targets set by Wall Street analysts indicates a potential upside of 113.9% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See an 114% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?

HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 2:55 p.m. Eastern Time.

Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates

– ARCALYST ® (rilonacept) net revenue of $27.0 million in Q2 2022 –

News for Kiniksa Pharmaceuticals Ltd Stock (KNSA)